NATALEE 6年结果出来了！#ESMO26
6年生存期差异为2.1。
感谢 @Annals_Oncology 报告后续治疗数据！
👉对照组中发生远处复发的患者仅44.4%接受了一线CDK4/6i
在CDK4/6i是转移性疾病标准治疗的情况下，这一生存期差异是否真的能为临床实践提供参考？
在我看来，答案是否定的。
2604 浏览 · 31 赞 · 11 转发 · 2 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- douglas@deathinsep
@Timothee_MD @Annals_Oncology But if they use in second line, SONIA suggested that the overall survival benefit with iCDK in metastatic disease would be similar
- Cohen carine@carinecccc
@Timothee_MD @Annals_Oncology They hided the OS in thé Europe region alone, which represents 59% of thé whole trial, And they dropped thé table of deaths due to other causes than breast cancer to conceal the many cardiovascular events!
来源：Timothée Olivier, MD · x.com